Aerovate Therapeutics, Inc. (AVTE)
Largest Insider Buys in Sector
AVTE Stock Price History Chart
AVTE Stock Performance
About Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Insider Activity of Aerovate Therapeutics, Inc.
Over the last 12 months, insiders at Aerovate Therapeutics, Inc. have bought $1.55M and sold $7.68M worth of Aerovate Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aerovate Therapeutics, Inc. have bought $71.77M and sold $8.79M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $38.75M.
The last purchase of 928,110 shares for transaction amount of $1.55M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑06‑17.
List of Insider Buy and Sell Transactions, Aerovate Therapeutics, Inc.
| 2024-06-17 | 928,110 0.2418% | $1.67 | $1.55M | +15.15% | ||||
| 2024-06-14 | Sale | SEE REMARKS | 15,000 0.0586% | $25.03 | $375,450 | -92.28% | ||
| 2024-06-14 | Sale | CHIEF TECHNICAL OFFICER | 10,600 0.0413% | $25.00 | $265,000 | -92.28% | ||
| 2024-06-13 | Sale | CHIEF MEDICAL OFFICER | 6,000 0.0229% | $24.50 | $147,000 | -92.27% | ||
| 2024-05-17 | Sale | CHIEF MEDICAL OFFICER | 4,000 0.0136% | $21.08 | $84,332 | -90.47% | ||
| 2024-05-16 | Sale | CHIEF EXECUTIVE OFFICER | 10,000 0.0347% | $21.58 | $215,755 | -90.96% | ||
| 2024-05-02 | Sale | CHIEF TECHNICAL OFFICER | 1,981 0.007% | $21.02 | $41,631 | -90.19% | ||
| 2024-05-01 | Sale | CHIEF EXECUTIVE OFFICER | 11,357 0.0386% | $20.34 | $230,946 | -90.19% | ||
| 2024-04-17 | Sale | CHIEF MEDICAL OFFICER | 4,000 0.0143% | $22.38 | $89,522 | -90.71% | ||
| 2024-04-17 | Sale | SEE REMARKS | 6,853 0.0245% | $22.37 | $153,327 | -90.71% | ||
| 2024-04-16 | Sale | CHIEF EXECUTIVE OFFICER | 10,000 0.0375% | $24.70 | $246,971 | -91.19% | ||
| 2024-04-10 | Sale | SEE REMARKS | 7,500 0.0268% | $26.85 | $201,392 | -92.19% | ||
| 2024-04-09 | Sale | director | 11,882 0.0428% | $28.15 | $334,478 | -92.44% | ||
| 2024-04-01 | Sale | SEE REMARKS | 12,495 0.0455% | $31.23 | $390,208 | -92.76% | ||
| 2024-04-01 | Sale | SEE REMARKS | 3,325 0.0124% | $31.97 | $106,317 | -92.76% | ||
| 2024-04-01 | Sale | CHIEF TECHNICAL OFFICER | 5,300 0.0181% | $29.19 | $154,697 | -92.76% | ||
| 2024-04-01 | Sale | CHIEF EXECUTIVE OFFICER | 10,000 0.035% | $30.00 | $300,033 | -92.76% | ||
| 2024-03-28 | Sale | CHIEF MEDICAL OFFICER | 9,000 0.0322% | $29.50 | $265,500 | -92.38% | ||
| 2024-03-27 | Sale | SEE REMARKS | 11,068 0.0393% | $27.97 | $309,519 | -91.96% | ||
| 2024-03-25 | Sale | SEE REMARKS | 3,432 0.0129% | $28.01 | $96,119 | -91.35% |
Insider Historical Profitability
| RA CAPITAL MANAGEMENT, L.P. | 7893678 27.3443% | $2.78 | 2 | 0 | <0.0001% | |
| GRAYZEL DAVID S. | director | 14502 0.0502% | $2.78 | 1 | 1 | <0.0001% |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 3758686 13.0204% | $2.78 | 1 | 0 | <0.0001% |
| Katabi Maha | 3758686 13.0204% | $2.78 | 1 | 0 | <0.0001% | |
| Atlas Venture Fund XII, L.P. | 10 percent owner | 3103879 10.7521% | $2.78 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $244.37M | 28.69 | 8.26M | 0% | +$0 | 0.25 | |
| Sofinnova | $111.14M | 13.05 | 3.76M | 0% | +$0 | 0.23 | |
| Tcg Crossover Management Llc | $65.09M | 7.64 | 2.2M | 0% | +$0 | 0.1 | |
| Atlas Venture Life Science Advisors Llc | $60.3M | 7.08 | 2.04M | 0% | +$0 | 5.6 | |
| Baker Bros Advisors LP | $49.69M | 5.83 | 1.68M | 0% | +$0 | 0.36 |